{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-029174","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.069663+00:00","generated_at":"2026-05-31T16:01:35.158508+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial","bullets":["$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.","NEXICART-2 U.S. Phase 1b/2 trial to evaluate NXC-201; builds on prior ex-U.S. data showing 92% overall response rate.","NXC-201 is the only CAR-T therapy in development for AL Amyloidosis and has Orphan Drug Designation from FDA and EMA.","No FDA approved drugs currently for relapsed/refractory AL Amyloidosis; CIRM grant adds non-dilutive funding to ongoing clinical program."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-029174","json":"https://secwatch.observer/filing/0001493152-24-029174.json","markdown":"https://secwatch.observer/filing/0001493152-24-029174.md","text":"https://secwatch.observer/filing/0001493152-24-029174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224029174/0001493152-24-029174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224029174/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:01:35.158508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}